Safety study of IVMED-85 eye drops in healthy adults
Part of Eyes & vision clinical trials.
This phase 1 trial tests the safety of an investigational eye drop called IVMED-85 in healthy adults aged 18-49. Participants will receive the eye drops and be monitored for any side effects over 6 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 49 years old.
- You must be generally healthy, with no major eye or health conditions.
- Your vision must be good (20/30 or better) in each eye.
- You must be willing to stop using other eye drops for the study (except artificial tears).
- You must not wear mascara or swim in an indoor pool for 6 weeks.
- You must not have a copper allergy or related condition (like Wilson's disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new eye drop called BT01001 is safe for healthy adults. You may join if you have good overall and eye health, and do not use contact lenses or have chronic eye problems.
This trial tests a new eye drop called PAN-90806 in healthy people to see if it is safe and how the body handles it. Participants will receive the eye drops and be closely monitored.
This study tests an experimental eye drop called IVMED-85 to see if it can slow down or stop the progression of nearsightedness (myopia) in children and teenagers. If it works, it might help keep their vision from getting worse as they grow.
This study tests an experimental eye drop medication in healthy adults to see if it is safe and how the body handles it. It may help develop a new treatment for eye conditions.
This study tests an eye ointment (RC017) in healthy adults to check its safety and how the body processes it. It may help doctors understand if this treatment for eye conditions is safe before it's used in patients.
This study tests an investigational eye drop called OT202 to see if it helps people with moderate to severe dry eye. If you join, you'll receive either the study drug or a placebo (no active ingredient) and have your symptoms and eye health monitored for several months.
Hear when a new Safety Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.